Welcome

This website is intended for international healthcare professionals with an interest in the treatment of Nocturia. By clicking the link below you are declaring and confirming that you are a healthcare professional. Please answer a few short questions about this resource centre.

You are here

Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder

By O. Yokoyama, S. Hiro, S. Hotta, S. Mogami and H. Yamagami.

Urology, Volume 83, Issue 4, April 2014, Pages 750-755

Editor’s comments:
The present article represents a valid example demonstrating that an adequate selection of patients with nocturia, by distinguishing  those affected by nocturnal polyuria from those with OAB  and reduced bladder capacity, can help to well control the disabling symptom. This is a randomized placebo controlled trial of fesoterodine fumarate 4 and 8 mg once daily in 555 Asian adults affected by OAB with at least ≥ 1 nocturnal micturition/24h. As parameters, changes from baseline to week 12 in frequency of nocturnal voiding, nocturnal urine volume and time of undisturbed sleep have been also examined. It was observed that fesoterodine 4 and 8 mg once daily can be effective in treating nocturia only in patients who did not present with a nocturnal polyuria index >33%. Particularly, in the latter patients’ population, the decrease in nocturnal micturitions was significantly higher with fesoterodine 8 mg vs placebo; fesoterodine 4 mg was able to induce a significant reduction in  nocturnal urine volume anda  significant amelioration in time of undisturbed sleep, vs placebo. Finally, also sleep energy scores, as evaluated by the King’s Health Questionnaire appeared significantly better.